Elevated serum levels of SLC3A2 have been detected in patients with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), which also corresponded to the increased mRNA level of SLC3A2 in cancer tissues [199]. Here, SLC3A2 is linked to lung adenocarcinoma.